Omuro, Antonio

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 4,071

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine

Cancer Genomics and DiagnosticsBRCA gene mutations in cancer

Cited by 3,380

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143

Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., Voloschin, A., Ramkissoon, S. H., Ligon, K. L., Latek, R., et al. (2018) · Neuro-Oncology

Cancer Immunotherapy and BiomarkersGlioma Diagnosis and Treatment

Cited by 486

OS10.3 Randomized Phase 3 Study Evaluating the Efficacy and Safety of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: CheckMate 143

Reardon, D. A., Omuro, A., Brandes, A. A., Rieger, J., Wick, A., Sepulveda, J., Phuphanich, S., de Souza, P., Ahluwalia, M. S., Lim, M., et al. (2017) · Neuro-Oncology

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 325

A Shortage of Neurologists – We Must Act Now: A Report From the AAN 2019 Transforming Leaders Program

Majersik, J. J., Ahmed, A., Chen, I.-H. A., Shill, H., Hanes, G. P., Pelak, V. S., Hopp, J. L., Omuro, A., Kluger, B., & Leslie-Mazwi, T. (2021) · Neurology

Global Health Workforce IssuesDiversity and Career in Medicine

Cited by 133

A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.

Sampson, J. H., Omuro, A. M. P., Preusser, M., Lim, M., Butowski, N. A., Cloughesy, T. F., Strauss, L. C., Latek, R. R., Paliwal, P., Weller, M., et al. (2016) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 53

Using Adversarial Images to Assess the Robustness of Deep Learning Models Trained on Diagnostic Images in Oncology

Joel, M. Z., Umrao, S., Chang, E., Choi, R., Yang, D. X., Duncan, J. S., Omuro, A., Herbst, R., Krumholz, H. M., & Aneja, S. (2022) · JCO Clinical Cancer Informatics

Adversarial Robustness in Machine LearningDigital Media Forensic Detection

Cited by 51

A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM)

Sarkaria, J. N., Mrugala, M. M., Jaeckle, K. A., Burns, T. C., Vaubel, R. A., Parney, I. F., Chaichana, K., Clement, P. M., Martinez-Garcia, M., Sepulveda Sanchez, J. M., et al. (2024) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentCancer-related Molecular Pathways

Cited by 3